Nabriva Therapeutics AG (NBRVF)

Currency in USD
0.0001
0.0000(0.00%)
Closed·
NBRVF Scorecard
Full Analysis
Stock generally trades with low price volatility
Earnings results expected today
Trading near 52-week Low
NBRVF is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.00010.0001
52 wk Range
0.00010.0100
Key Statistics
Prev. Close
0.0001
Open
0.0001
Day's Range
0.0001-0.0001
52 wk Range
0.0001-0.01
Volume
-
Average Volume (3m)
869
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NBRVF Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Nabriva Therapeutics AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Compare NBRVF to Peers and Sector

Metrics to compare
NBRVF
Peers
Sector
Relationship
P/E Ratio
0.0x−2.1x−0.5x
PEG Ratio
0.000.020.00
Price/Book
0.0x0.8x2.6x
Price / LTM Sales
0.0x1.0x3.3x
Upside (Analyst Target)
0.0%163.4%43.5%
Fair Value Upside
Unlock15.0%6.9%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NBRVF Income Statement

FAQ

What Stock Exchange Does Nabriva Therapeutics Trade On?

Nabriva Therapeutics is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Nabriva Therapeutics?

The stock symbol for Nabriva Therapeutics is "NBRVF."

What Is the Nabriva Therapeutics Market Cap?

As of today, Nabriva Therapeutics market cap is 323.00.

What Is Nabriva Therapeutics's Earnings Per Share (TTM)?

The Nabriva Therapeutics EPS (TTM) is -17.90.

When Is the Next Nabriva Therapeutics Earnings Date?

Nabriva Therapeutics will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is NBRVF a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Nabriva Therapeutics Stock Split?

Nabriva Therapeutics has split 2 times.

How Many Employees Does Nabriva Therapeutics Have?

Nabriva Therapeutics has 39 employees.

What is the current trading status of Nabriva Therapeutics (NBRVF)?

As of 07 Aug 2025, Nabriva Therapeutics (NBRVF) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.01.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.